59 related articles for article (PubMed ID: 24597345)
1. [Perspective of personalized (precise) cancer therapy based on predictive biomarkers].
Osera S; Yoshino T
Nihon Rinsho; 2014 Jan; 72(1):29-34. PubMed ID: 24597345
[TBL] [Abstract][Full Text] [Related]
2. [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer].
Soeda H; Shimodaira H; Ishioka C
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1079-83. PubMed ID: 21772090
[TBL] [Abstract][Full Text] [Related]
3. Development of molecular biomarkers in individualized treatment of colorectal cancer.
De Mattos-Arruda L; Dienstmann R; Tabernero J
Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
Okada Y; Miyamoto H; Goji T; Takayama T
Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
[TBL] [Abstract][Full Text] [Related]
5. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
7. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.
Berg M; Soreide K
Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375
[TBL] [Abstract][Full Text] [Related]
8. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.
Yarom N; Jonker DJ
Discov Med; 2011 Feb; 11(57):95-105. PubMed ID: 21356164
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
Asghar U; Hawkes E; Cunningham D
Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
[TBL] [Abstract][Full Text] [Related]
10. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.
Troiani T; Zappavigna S; Martinelli E; Addeo SR; Stiuso P; Ciardiello F; Caraglia M
Expert Opin Biol Ther; 2013 Feb; 13(2):241-55. PubMed ID: 23281932
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.
Heinemann V; Douillard JY; Ducreux M; Peeters M
Cancer Treat Rev; 2013 Oct; 39(6):592-601. PubMed ID: 23375249
[TBL] [Abstract][Full Text] [Related]
12. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
14. Molecular predictors of response to chemotherapy in colorectal cancer.
Dienstmann R; Vilar E; Tabernero J
Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
[TBL] [Abstract][Full Text] [Related]
15. Personalized treatment for patients with colorectal cancer: role of biomarkers.
Duffy MJ
Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
[TBL] [Abstract][Full Text] [Related]
16. Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways.
García-Roman S; Garzón-Ibáñez M; Bertrán-Alamillo J; Jordana-Ariza N; Giménez-Capitán A; García-Peláez B; Vives-Usano M; Codony-Servat J; d'Hondt E; Rosell R; Molina-Vila MÁ
Transl Oncol; 2024 Feb; 40():101878. PubMed ID: 38183801
[TBL] [Abstract][Full Text] [Related]
17. The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.
Moorcraft SY; Smyth EC; Cunningham D
Therap Adv Gastroenterol; 2013 Sep; 6(5):381-95. PubMed ID: 24003339
[TBL] [Abstract][Full Text] [Related]
18. Platycodin D sensitizes
Liu Y; Tian S; Yi B; Feng Z; Chu T; Liu J; Zhang C; Zhang S; Wang Y
Front Oncol; 2022; 12():1046143. PubMed ID: 36387129
[TBL] [Abstract][Full Text] [Related]
19. PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target.
Salvatore L; Calegari MA; Loupakis F; Fassan M; Di Stefano B; Bensi M; Bria E; Tortora G
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31717544
[TBL] [Abstract][Full Text] [Related]
20. Relating biomarkers to efficacy and the efficacy curve: a review of EGFR therapies in oncology.
Stroupe SD; Colpitts TL
Per Med; 2010 Jan; 7(1):19-31. PubMed ID: 29783375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
